Deniz Razon

Deniz Razon

Head of Corporate Development

Deniz Razon is the Head of Corporate Development at Servier Pharmaceuticals. In this role, Deniz is responsible for leading strategy development for each therapeutic area, establishing the operational execution of the acquisition process from deal assessment to management, and representing the United States with global business development and licensing colleagues. Further, she is a Board member of Servier Pharmaceuticals as well as the Gateway Foundation for Cancer Research.

Over 20 years, Deniz has garnered broad pharmaceutical commercial experience across various therapeutic areas. Prior to joining Servier, Deniz held several roles at Shire including the Vice President of Operations for the Internal Medicine and Oncology franchise and Vice President of United States Sales for Lysosomal Storage Disorders and Oncology. Deniz also spent several years at Baxter and Baxalta where she played a pivotal role in preparing the Oncology franchise for growth through comprehensive analyses of licensing and acquisition opportunities and creating commercialization plans for internal and new partnership assets.

Deniz graduated Magna Cum Laude from Mount Holyoke College with a Bachelor of Arts in International Relations and Economics. She graduated with honors from University of Michigan with her Master of Business Administration in Strategy and Marketing.

To learn more about Deniz connect with her on LinkedIn.

More from Servier

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More

Governance

Servier Pharmaceuticals is an independent, privately held United States company launched by Servier Group, a unique global organization, and is governed by a non-profit foundation.

Learn More

History

Servier has a 65-year history of helping provide innovative medicines to patients globally. In the United States, Servier intends to uphold and build upon that history. 

Learn More